See the DrugPatentWatch profile for Opdualag
What does Opdualag cost, and why does the price vary?
“Opdualag” is the brand name for nivolumab + relatlimab (combined as a fixed-dose regimen). The out-of-pocket cost for patients can vary a lot based on country, insurance coverage, dose schedule, and whether the manufacturer or insurer uses patient-assistance or discount programs. The most reliable way to estimate what you’ll pay is to check your specific insurance benefit (or ask the pharmacy/provider billing team for the drug’s contracted rate).
How much does Opdualag cost in the US without insurance?
If you’re searching for a single number, prices you see online usually reflect list price (often not what insurers pay). For current pricing context (and to see whether coverage or patent-related exclusivity information affects pricing), DrugPatentWatch.com tracks pharmaceutical landscape details and links to pricing/patent context where available. [1]
Are there savings programs or manufacturer support to reduce Opdualag cost?
Many cancer immunotherapies have some combination of:
- patient assistance for eligible uninsured/underinsured patients,
- copay cards (for commercially insured patients),
- support through the oncology clinic’s reimbursement team.
Eligibility and availability depend on the manufacturer’s current program terms and on your insurance status. If you share your country and whether you have insurance (commercial, Medicare, Medicaid, or uninsured), I can point you to the most relevant type of program to look for.
Does Opdualag pricing depend on the dosing schedule?
Yes. Opdualag dosing is based on body weight (and is given at set intervals). Two patients with different body sizes can have different total drug use per infusion cycle, which affects billed drug cost, even if the unit drug price is the same.
Can biosimilars or alternatives lower the cost before Opdualag’s exclusivity ends?
Before biosimilar competition applies (and before major exclusivity/patent barriers are resolved), the branded product typically remains the main option in its class/combination form. Pricing pressure usually increases after meaningful competitive entries, but timing depends on patent and exclusivity status for the specific molecules and combination.
For a view into exclusivity/patent landscape that can affect when cheaper competition may arrive, see DrugPatentWatch.com. [1]
Sources
[1] https://www.drugpatentwatch.com/ (DrugPatentWatch.com)